Background: Metabolic skeletal changes particularly metabolic super scan (MSS) may provide unsuitable soil for survival and growth of tumor cells in cancer breast patients. We aimed to verify the presence of MSS in cancer breast patients in correlation with the available biomarker for bone metabolism and to explore its influence on the frequency of bone metastases compared to patients without MSS features. Methods: From July 2008 to December 2010, 450 histo-pathologically proved breast cancer patients referred to nuclear medicine department in national cancer institute (NCI), Cairo University, Egypt underwent whole body bone Scan. Bone metabolism was evaluated by laboratory biomarkers of serum alkaline phosphatase (ALP), serum calcium and parathormone (PTH) levels in addition to serum creatinine to assess renal function. Statistical correlations were done between bone scan, clinico-pathological data, radiological findings and serum biomarkers. Follow up within 16-24 months was done. Results: Based on the presence or absence of MSS features, breast cancer patients were classified into two groups: I) MSS group: -included 99 patients, with a mean age of 60.5 years ± 19.5. (II) Non-MSS group: included 351 patients with a mean age of 57 years ± 22.0. Patients based data analysis showed that MSS was seen in 22% of the studied breast cancer patients with more prevalence in the post menopausal women and those treated with hormonal and bisphosphonate therapy. Moreover, a significantly lower frequency of bone metastases was noticed in MSS group (8%) compared to Non-MSS (18.2%) (P<0.05). On the other hand sensitivity, accuracy and PPV for detection of bone metastases were significantly lower in MSS group (75%,75%,64%) compared to Non-MSS (90%, 88.6% and 75%) group respectively (P<0.05). A comparable low yield was obtained in PPV and specificity in both groups with no significant difference (P>0.05). Apart from significant higher level of alkaline phosphatase in MSS compared to Non-MSS group, no significant difference was noticed in the rest of the estimated metabolic biomarkers between both groups. Conclusion: MSS seems to be associated with low frequency of bone metastases in MSS compared to Non-MSS in cancer breast patients. MSS appears to be linked to menopausal status and treatment with hormonal and bisphosphonate therapy. Unfortunately MSS may have a negative impact on the accuracy of bone scan in detection of bone metastases.
INTRODUCTION:
The skeleton is among the most common metastatic sites in patients with breast cancer. In addition to portending a dire prognosis, bone metastases cause significant cumulative osseous morbidity [1, 2] . Development of skeletal metastases in breast cancer patients may entail a multistep process that involves sequences of molecular events directed by genetic alteration. However, the deposited tumour cells within the bone marrow will establish metastases and grow only if the marrow micro-environment is appropriate. The detailed step by step interaction between tumour cells and bone marrow microenvironment remained to be elucidated. However osteoclast seemed to play a central role in these events. Recently there is increased focus on the contribution of bone micro-environment to the development and progression of bone metastases [2, 3, 4, 5, 6] .
Biochemical markers are usually used to provide information regarding the changes occurring in bone metabolism especially osteoclastic activity [7] . Multiple limitations have been addressed by many authors that interfere with wide acceptance for their use in clinical practice. These include availability, cost, technical demands, multiplicity as well as lack of specificity and standardization. In addition, these laboratory assays suffer from cross reactivity, difference in immunoassays and are influenced by gender, age, diurnal variation as well as liver diseases [7, 8, 9, 10, 11] .
Bone scan is a widely accepted tool with high sensitivity and efficacy in early detection and follow up of bone metastases in patients with breast cancer [1, 2] . Bone scan may portray changes in skeletal metabolism, bone micro-environment and osteoclastic activity in a simple and easy way. MSS pattern entails peculiar scan features of diverse aetiology; however osteoclastic activity seems to play a major role through variable patho-physiological pathways. MSS changes may provide diffuse change in bone metabolism that disrupts the complex cross talk of cancer cells and cellular bone marrow microenvironment. To what extent these MSS changes may influence the development and growth of bone metastases remained unanswered crucial question in that field [10, 11, 13, 14, 15] .
There are limited data in the literature that addresses the frequency and influence of MSS changes in development and progress of bone metastases in cancer breast patients. This encouraged us to perform the current prospective study that aims to verify the presence of MSS in breast cancer patients and its correlation with the available bone biomarkers and to explore its effect on the development of bone metastases.
MATERIAL AND METHODS:
This study was approved by the ethics committee at (NCI), Cairo University, Egypt. The acquisition was carried out in anterior and posterior views simultaneously with 180 degree positioning for the dual head gamma camera. The gamma camera was equipped with low energy general purpose (parallel hole) collimator. A Tc-99m photo peak of 140 KeV with a 20% window was used. The matrix used was 265x1028. Imaging was performed while the patient was lying supine at 5 cm distance from the collimator with 10 cm/min scan speed. Occasionally additional localized detailed images in anterior and posterior views were obtained for better exploration of indeterminate lesions using a 256 x 256 matrix. The laboratory assessment based on chemo-luminescence assay of serum alkaline phosphatase (ALP), calcium (Ca ++) and occasionally parathormone (PTH) levels were done as markers for bone metabolism. Serum creatinine was done as an indicator for kidney function. Male patients with breast cancer were excluded from the current study. 
STATISTICAL ANALYSIS:
Values of laboratory data were expressed as mean ± SD. Sensitivity, specificity, accuracy, positive and negative predictive values for bone scan results were calculated using the Willson score which was generated by the Open Epi program. The significance of the correlations was assessed with the Fisher z test. In addition, the multiple comparisons were adjusted by using the Bonferroni-Holm method. Pvalues less than 0.05 were considered to indicate significant differences.
RESULTS:
Interpretation of bone scans was carried out with complete unawareness of the rest of the patients' data. Six criteria were listed for the diagnosis of MSS features, namely: diffusely Enhanced skeletal uptake, high bone to background ratio, prominent long bones uptake, Non visualization of both kidneys, beading of the costo-chondral junctions and prominent sternal uptake. At least four criteria were required for diagnosis of MSS. Based on the presence or absence of MSS features breast cancer patients were divided into two groups; MSS group that included 99 patients (Figure 1) , with mean age of 60.5 years ± 19.5 and Non-MSS group that included 351 patients with mean age of 57 years ± 22.0. The main clinico-pathological patient's criteria in both groups are illustrated in table 1. The included breast cancer patients were treated according to the standard NCI treatment protocols. Table 2 shows differences in treatment between MSS and Non-MSS groups. As shown in table 2 MSS seemed to be linked to hormonal and bisphosphonates treatment rather than other systemic therapy. 
Laboratory Results:
In the current study the values of serum level of creatinine, calcium and alkaline phosphatase were estimated in both groups. 
DISCUSSION:
Breast cancer is the most common malignant disease in women. It forms a major health problem in western countries. Bones metastases are frequent in patients with breast cancer especially the advanced one. In addition to its relatively poor prognosis, bone metastases cause a significant cumulative morbidity in breast cancer patients [1, 2] . In spite of its clinical importance, the underlying cellular and molecular mechanism driving bone metastases in breast cancer patients remains elusive. Recently, in addition to the progress in understanding the phenotype of cancer cells, there is increased focus on the tumour microenvironment and its influence on the development and growth of bone metastases in breast cancer. Better understanding of the influence of cellular changes in micro-environment of bone on the entire multi-step metastatic process is required in clinical practice [4, 5, 15, 17, 18] . It was possible in the present study to explore the probability of changes in bone micro-environment via using MSS and its influence on frequency of bone metastases in patients with breast cancer. In the current study, MSS features were seen in 22 % of the studied breast cancer patients. These MSS features were more frequent in post-menopausal patients especially those with positive hormonal receptors status compared to premenopausal and negative hormonal receptor status. The major action of estrogen hormone is to inhibit osteoclastic activity which occurs through different several mechanisms. The fall in estrogen at time of menopause results in elimination of its inhibitory effect on the osteoclasts and consequent enhanced bone resorption. As osteoblastic response follows osteoclastic activity in co-ordinated pattern, the net result will be enhanced skeletal uptake to bone tracer. This preferential bone uptake produces MSS features [11, 12, 17, 18, 19, 20] . 4, 17, 19, 20, 21, 22, 23, 24 .
Further elaborate research data are needed focusing on the relation of characteristic changes in each micro-environment which may improve intervention for the sake of patient.
In agreement with published data, the current study shows a negative impact for MSS changes on the reliability of bone scan for detection of bone metastases in MSS compared to Non-MSS group of patients [13, 15, 18] . This was more obvious in sensitivity, NPV and overall accuracy rather than specificity and PPV. MSS may hide a true positive lesion leading to more false negative results. In addition the lesions complicating MSS may further lower the specificity of bone scan for detection of bone metastases. Renal osteodystrophy is a well known cause for MSS 25 . In attempt to explore the contribution of renal factor in the existed MSS, serum creatinine level was tested in the 450 studied breast cancer patients. There were no significant differences in the values of serum creatinine level in MSS group compared to non MSS. This tends to reduce renal osteodystrophy as a contributing factor in MSS changes in the current study. In respect to the studied bio-markers there was a significant increase in the values of alkaline phosphatase in both groups. On the other hand similar values for calcium and parathyroid hormone were recorded for both MSS and Non-MSS groups with no significant difference in-between. These results disagree with other authors [7, 26] who demonstrate elevated PTH and serum calcium levels in MSS compared to Non-MSS patients. This discrepancy may be attributed to different pathophysiological mechanism for MSS as well as variation in duration and different population of the study. The strength of the study lies in its novel prospective nature in addressing the effect of MSS on the frequency of bone metastases in breast cancer patients. The study enclosed female breast cancer patients of similar age group. The limitation of the study is inability to correlate MSS with more specific bone biomarker. This study runs on a short term basis on heterogeneous group of patients with variation in duration of disease and different therapeutic modalities. The accuracy of the results based on a short term follow up period. The study did not correlate the magnitude and severity of MSS with the duration of the used hormonal or bisphosphonate therapy. Moreover it did not consider the aetiological based potential characteristic difference in MSS pattern among the studied breast cancer patient.
CONCLUSION:
MSS was seen in 22% of the studied breast cancer patients. MSS was more prevalent in post-menopausal patient, and/or those treated with hormonal and bisphosphonate therapy. MSS tends to reduce the frequency of bone metastases in breast cancer patients. However it has a negative impact on the accuracy of bone scan results in identification of bone metastases.
